JP2004516823A5 - - Google Patents

Download PDF

Info

Publication number
JP2004516823A5
JP2004516823A5 JP2002530779A JP2002530779A JP2004516823A5 JP 2004516823 A5 JP2004516823 A5 JP 2004516823A5 JP 2002530779 A JP2002530779 A JP 2002530779A JP 2002530779 A JP2002530779 A JP 2002530779A JP 2004516823 A5 JP2004516823 A5 JP 2004516823A5
Authority
JP
Japan
Prior art keywords
protein
antibody
phosphorylated
specificity
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002530779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004516823A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/030186 external-priority patent/WO2002027017A2/en
Publication of JP2004516823A publication Critical patent/JP2004516823A/ja
Publication of JP2004516823A5 publication Critical patent/JP2004516823A5/ja
Withdrawn legal-status Critical Current

Links

JP2002530779A 2000-09-27 2001-09-27 タンパク質に対するホスホキナーゼ活性の定量のための方法 Withdrawn JP2004516823A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23562000P 2000-09-27 2000-09-27
PCT/US2001/030186 WO2002027017A2 (en) 2000-09-27 2001-09-27 Method for quantifying phosphokinase activity on proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006079226A Division JP2006225396A (ja) 2000-09-27 2006-03-22 タンパク質に対するホスホキナーゼ活性の定量のための方法

Publications (2)

Publication Number Publication Date
JP2004516823A JP2004516823A (ja) 2004-06-10
JP2004516823A5 true JP2004516823A5 (https=) 2005-04-28

Family

ID=22886277

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002530779A Withdrawn JP2004516823A (ja) 2000-09-27 2001-09-27 タンパク質に対するホスホキナーゼ活性の定量のための方法
JP2006079226A Pending JP2006225396A (ja) 2000-09-27 2006-03-22 タンパク質に対するホスホキナーゼ活性の定量のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006079226A Pending JP2006225396A (ja) 2000-09-27 2006-03-22 タンパク質に対するホスホキナーゼ活性の定量のための方法

Country Status (7)

Country Link
US (4) US20030162230A1 (https=)
EP (3) EP1328812B1 (https=)
JP (2) JP2004516823A (https=)
AT (1) ATE416385T1 (https=)
CA (1) CA2423979C (https=)
DE (1) DE60136840D1 (https=)
WO (1) WO2002027017A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
GB0208104D0 (en) * 2002-04-09 2002-05-22 Univ Dundee Method
US7217796B2 (en) 2002-05-24 2007-05-15 Schering Corporation Neutralizing human anti-IGFR antibody
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7781173B2 (en) * 2003-09-25 2010-08-24 Life Technologies Corporation Homogeneous populations of molecules
JP2007510434A (ja) 2003-11-12 2007-04-26 シェーリング コーポレイション 多重遺伝子発現のためのプラスミドシステム
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP2283831A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
EP1910828A4 (en) * 2005-07-01 2012-03-14 Univ St Louis PHOSPHOSPECTIVE CHEMOKIN RECEPTOR ANTIBODIES
WO2007133688A2 (en) * 2006-05-12 2007-11-22 Cell Signaling Technology, Inc. Reagents for the detection of tyrosine phosphorylation in brain ischemia signaling pathways
US20100160339A1 (en) * 2007-05-21 2010-06-24 Mayo Foundation For Medical Education And Research Treating pancreatitis
KR101612442B1 (ko) 2008-05-13 2016-04-15 삼성전자주식회사 컨텐츠 시청 제한 정보의 제공 및 이용을 위한 방법 및장치
US20130231305A1 (en) * 2010-03-29 2013-09-05 Medvet Science Pty. Ltd. Method of Modulating Protein 14-3-3 Functionality By Facilitating or Inhibiting Phosphorylation
US20170016900A1 (en) 2010-09-07 2017-01-19 Stephen G. Marx Kit for monitoring, detecting and staging gvhd
ES2692833T3 (es) * 2010-09-07 2018-12-05 Stephen G. Marx Kit para controlar, detectar y estadificar GVHD
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
HRP20200384T1 (hr) 2013-12-20 2020-06-12 F. Hoffmann - La Roche Ag Humanizirana anti-tau(ps422) protutijela i načini uporabe
WO2015099094A1 (ja) * 2013-12-27 2015-07-02 国立大学法人東京医科歯科大学 アルツハイマー病及び前頭側頭葉変性症の診断方法、診断薬、治療薬、及びこれら薬剤のスクリーニング方法
AU2015240088B2 (en) * 2014-03-31 2021-07-22 Merck Patent Gmbh Method for detecting protein modifications using specific antibodies
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
AU2017225907B2 (en) * 2016-03-01 2023-11-23 Celosia Therapeutics Pty Ltd Use of phosphorylated tau and p38gamma to treat a neurological condition
PL3484916T3 (pl) 2016-07-12 2021-07-19 H. Lundbeck A/S Przeciwciała swoiste wobec hiperfosforylowanego białka tau i sposoby ich zastosowania
ES2791962T3 (es) * 2016-11-21 2020-11-06 Univ Ruhr Bochum Ensayo combinado para el diagnóstico diferencial de la enfermedad de Alzheimer
WO2018127519A1 (en) 2017-01-04 2018-07-12 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
KR20200100726A (ko) * 2017-12-18 2020-08-26 예일 유니버시티 섬유증 치료용 화합물 및 조성물
MA53338A (fr) 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
US11085935B2 (en) * 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP4028775A4 (en) 2019-09-10 2023-04-12 Washington University BLOOD-BASED TEST FOR DIAGNOSIS AND TREATMENT BASED ON SITE-SPECIFIC TAU PHOSPHORYLATION

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2354288C2 (de) 1973-10-30 1976-01-02 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Aminophenylalkyläthern
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5733734A (en) * 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
JPH05126833A (ja) 1991-10-31 1993-05-21 Tosoh Corp チロシンキナ−ゼ活性の免疫化学的測定法及びそのキツト
ATE398176T1 (de) * 1991-12-06 2008-07-15 Max Planck Gesellschaft Phosphorylierungsepitope aus dem tau-protein zur diagnose und behandlung der alzheimer-krankheit
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
ES2268684T3 (es) 1992-04-10 2007-03-16 Dana-Farber Cancer Institute, Inc. Inmunodeteccion de fosfoproteina especifica al estado de activacion.
DE69318420T2 (de) * 1992-12-14 1999-01-28 Naamloze Vennootschap Innogenetics S.A., Gent Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
US6924361B1 (en) 1993-11-02 2005-08-02 Phosphoproteomics Llc Phosphopeptide-specific antibodies that are activity specific; methods of production and antibody uses
AU697142B2 (en) * 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
DK0737208T3 (da) * 1993-12-21 2006-11-27 Innogenetics Nv Monoklonale antistoffer, der er specifikke for PHF-tau, hybridomaer, der secernerer dem, og antigen-genkendelse for disse antistoffer og deres anvendelsesmuligheder
US6348310B1 (en) * 1994-03-04 2002-02-19 Promega Corporation Quantitation of individual protein kinase activity
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
EP0772634B1 (en) * 1994-07-29 2003-03-12 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
US6001580A (en) * 1995-03-28 1999-12-14 Takeda Chemical Industries, Inc. Method for assaying ERK2 map kinase
AU753557B2 (en) * 1997-11-07 2002-10-24 Vasopharm Biotech Gmbh Antibodies against phosphorylated vasp (vasodilator-stimulated phosphoprotein), hybridoma cells for their preparation, and their use
DE69811724T2 (de) * 1997-12-05 2003-10-16 Pharmacia & Upjohn Co., Kalamazoo Fluoreszenz-basierte hts-(high throughput screening)assayverfahren für proteinkinase und phosphatase
GB9803399D0 (en) * 1998-02-19 1998-04-15 Imp Cancer Res Tech Protein kinase c
JP2000034300A (ja) * 1998-07-17 2000-02-02 Mitsubishi Chemicals Corp 抗リン酸化タウ蛋白質抗体及びそれを用いるアルツハイマー病の検出方法
US6309863B1 (en) 1999-01-25 2001-10-30 Brookhaven Science Associates Methods for generating phosphorylation site-specific immunological reagents
AU5604900A (en) * 1999-06-09 2000-12-28 Ljl Biosystems, Inc. Phosphorylation assays
EP1207395A4 (en) * 1999-08-04 2003-08-13 Med & Biological Lab Co Ltd METHOD FOR MEASURING KINASE ACTIVITY OR CYCLINE / CDK COMPLEX
DE60123752T2 (de) * 2000-01-24 2007-08-23 Innogenetics N.V. Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
US20030166016A1 (en) 2000-04-28 2003-09-04 Foster Barbara A. Assay methods for cyclin dependent kinases
US20030162230A1 (en) 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins

Similar Documents

Publication Publication Date Title
JP2004516823A5 (https=)
CA2423979A1 (en) Method for quantifying phosphokinase activity on proteins
JP2006225396A5 (https=)
CN102648413B (zh) 多位置生物传感器及相关方法
ATE322558T1 (de) Sensible und multiplexe diagnostische tests zur proteinanalyse
EP1708745A4 (en) ANTIBODIES FOR ONCOGENIC STRAINS OF HPV AND METHOD FOR THEIR USE
JP2010521983A5 (https=)
JP2009542211A5 (https=)
WO2005007090A3 (en) Inhibitors of the map kinase pathway
WO2005059547A3 (en) Assay
CA2798562A1 (en) Methods and compositions for the diagnosis and treatment of thyroid cancer
JP2006502416A5 (https=)
WO2003087129A3 (en) Immunogenic peptides, and method of identifying same
WO2002095058A3 (en) Emission ratiometric indicators of phosphorylation
KR20120135842A (ko) pLDH에 특이적으로 결합하는 DNA 압타머
JP2005505757A5 (https=)
JP2007508527A5 (https=)
JP2023175819A5 (https=)
Yuzon et al. A novel paper-plastic microfluidic hybrid chip integrated with a lateral flow immunoassay for dengue nonstructural protein 1 antigen detection
JP2007526998A5 (https=)
JP2004530635A5 (https=)
SG129428A1 (en) Generic kinase assay
WO2004092741A3 (en) Mapping discontinuous antibody or aptamer epitopes for protein structure determination and other applications
WO2001021826A3 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
WO2008142664A3 (en) Exposed thymidine kinase 1 peptides, ligands and methods employing the same